LYNK PHARMACEUTICALS
LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.
LYNK PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2018-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.en.lynkpharma.com
Total Employee:
11+
Status:
Active
Contact:
+86 0571-8771117
Email Addresses:
[email protected]
Total Funding:
80 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Domain Not Resolving DigiCert SSL GeoTrust SSL Alibaba HiChina DNS Tengine
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Laekna Therapeutics
Laekna Therapeutics is a biotech company focusing on drug discovery and development.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Employees Featured
Founder
Investors List
Med-Fine Capital
Med-Fine Capital investment in Series B - LYNK Pharmaceuticals
HEDA Ventures
HEDA Ventures investment in Series B - LYNK Pharmaceuticals
Lilly Asia Ventures
Lilly Asia Ventures investment in Series B - LYNK Pharmaceuticals
Legend Capital
Legend Capital investment in Series B - LYNK Pharmaceuticals
New Alliance Capital
New Alliance Capital investment in Series B - LYNK Pharmaceuticals
Legend Capital
Legend Capital investment in Series A - LYNK Pharmaceuticals
Zheshang Industrial Group
Zheshang Industrial Group investment in Series A - LYNK Pharmaceuticals
Decheng Capital
Decheng Capital investment in Series A - LYNK Pharmaceuticals
Med-Fine Capital
Med-Fine Capital investment in Series A - LYNK Pharmaceuticals
Kaitai Capital
Kaitai Capital investment in Series A - LYNK Pharmaceuticals
Official Site Inspections
http://www.en.lynkpharma.com
Unable to get host informations!!!
More informations about "LYNK Pharmaceuticals"
凌科
凌科药业是一家处于临床阶段的创新药研发公司，致力于发现和开发用于治疗癌症以及免疫和炎症性疾病的新药。 凌科药业由来自辉瑞（Pfizer）、默克（Merck）和强生（Johnson & …See details»
LYNK Pharmaceuticals - Crunchbase Company Profile …
Contact Email [email protected] Phone Number +86 0571-8771117 LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and …See details»
关于我们 - Lynk Pharma
我们是一家处于临床阶段的创新药研发公司，致力于发现和开发用于治疗癌症以及免疫和炎症性疾病的新药。 公司由来自辉瑞（Pfizer)、默克（Merck）和强生（Johnson & Johnson）的资深 …See details»
Lynk Pharmaceuticals - LinkedIn
Lynk Pharmaceuticals is a clinical stage company dedicated to discovering and developing novel medicines to treat oncology, immunology and inflammatory diseases. Lynk was founded by …See details»
Lynk Pharmaceuticals Company Profile 2024: Valuation, Funding ...
Developer of small molecule drugs intended to treat tumors and autoimmune diseases. The company is committed to the research and development of small molecule FIC and BIC drugs …See details»
Lynk Pharmaceuticals Completes 200 Million RMB Series C1 …
May 31, 2023 · Founded in 2018 and headquartered in Hangzhou, China, Lynk Pharmaceuticals is a global innovative leader in the pharmaceutical industry dedicated to the development of …See details»
Lynk Pharmaceuticals announced the completion of Series B …
Aug 27, 2021 · For more information about Lynk Pharmaceuticals, please visit: https://www.lynkpharma.com. About Lilly Asia Ventures (LAV) Lilly Asia Ventures (LAV) is a …See details»
Lynk Pharmaceuticals inks $50M series B for 3 early-stage trials
Aug 27, 2021 · Lynk Pharmaceuticals picked up $50 million in series B funds Friday to bankroll three assets through phase 1 and 2 trials. The Hangzhou, China-based biotech has received …See details»
Lynk Pharmaceuticals Announces Positive Topline Data from Phase …
HANGZHOU, China, Aug. 23, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (referred to as "Lynk Pharmaceuticals"), an innovative clinical stage company, announced positive topline …See details»
Lynk Pharmaceuticals Announces Positive Topline Data from
Aug 23, 2023 · Lynk Pharmaceuticals Co., Ltd. (referred to as “Lynk Pharmaceuticals”), an innovative clinical stage company, announced positive topline data from a Phase II clinical trial …See details»
Lynk Pharmaceuticals Announced First Patient Dosed in Phase I …
HANGZHOU, China, Aug. 12, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative drug development company, announced …See details»
Lynk Pharmaceuticals Announces Positive Results for LNK01003
Apr 4, 2023 · Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’), an innovative clinical stage company, announced that it has recently completed phase I trials …See details»
Lynk Pharmaceuticals Announced First Patient Dosed in Phase I …
HANGZHOU, China, Aug. 12, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative drug development company, announced …See details»
Lynk Pharmaceuticals Announced First Patient Dosed in Phase II …
Dec 1, 2021 · LNK01001 is the first innovative drug developed by Lynk Pharmaceuticals, and is a selective kinase inhibitor for the treatment of autoimmune diseases.See details»
Lynk Pharmaceuticals Announced Clinical Approval in China of Its …
Jun 25, 2021 · To date, Lynk Pharmaceuticals has independently developed a number of Class I clinical innovative drugs, and has successfully transformed into a clinical stage company. For …See details»
Lynk Pharmaceuticals Announces First Patient Dosed in Phase
Jan 19, 2022 · LNK01001 is a JAK1 selective inhibitor for the treatment of autoimmune diseases. This study is a randomized, double-blind, placebo-controlled Phase II study evaluating the …See details»
Lynk Pharmaceuticals Announces Clinical Approval in China for Its …
Apr 22, 2022 · LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple inflammatory cytokines and block multiple signaling pathways related to psoriasis, and thus …See details»
Le conflit au Liban est particulièrement destructeur pour les soins …
6 days ago · Près de la moitié des attaques contre les soins de santé répertoriés au Liban depuis le 7 octobre 2023 - 65 sur 137 - ont été fatales à au moins un agent de santé ou un patient, a …See details»
Lynk Pharmaceuticals and Simcere announced Strategic …
HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to …See details»